All Episodes

October 26, 2022 29 mins

Thomas Kingsley Brown, Ph.D. started his research on ibogaine treatment in November of 2009 when he conducted interviews with patients at Pangea Biomedics (then in Playas de Tijuana, Mexico) and collected data for the purpose of studying changes in Quality of Life for those patients. Hearing about the transformative experiences of these people convinced him that ibogaine’s therapeutic value merited further study. 

Thomas recently published a comprehensive clinical summary of ibogaine use and treatments for the benefit of researchers and medical practitioners. He said “Ibogaine is the only treatment for opioid use disorder that consistently and significantly alleviates withdrawal symptoms that isn’t itself an opioid, and it does so with an effective level on par with methadone. 

Thomas's Research also shows that ibogaine not only interrupts addiction in the short term but also helps people control their drug addiction in the long term, leading to cessation or substantial reductions in problematic drug use. His co-founder Tom Feegel said their clients report that this process can take months of research, leaving them to depend on claims from unverifiable sources, and can even lead to conflicting conclusions based on partial or incomplete information. First and foremost we discuss if is ibogaine safe, as well as, why ibogaine should not have a bad reputation. 

Mark as Played

Advertise With Us

Popular Podcasts

Dateline NBC
The Nikki Glaser Podcast

The Nikki Glaser Podcast

Every week comedian and infamous roaster Nikki Glaser provides a fun, fast-paced, and brutally honest look into current pop-culture and her own personal life.

Stuff You Should Know

Stuff You Should Know

If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.

Music, radio and podcasts, all free. Listen online or download the iHeart App.

Connect

© 2024 iHeartMedia, Inc.